US-based biotechnology firm BioTime has entered into a sublicense agreement with Jade Therapeutics, a developer of ophthalmic sustained-release drug delivery platforms, for ophthalmic drug delivery applications of BioTime's HyStem ...
Tags: Health, Medicine, biotechnology
BioTime has signed an exclusive sublicense agreement and a supply agreement with Jade Therapeutics for ophthalmological drug delivery applications of HyStem technology. According to the agreement, BioTime will provide Jade with ...
Tags: HyStem technology, Biotime, Jade Therapeutics, ophthalmological drug